~~<i id='DA1B5AB373'><strike id='DA1B5AB373'><tt id='DA1B5AB373'><pre id='DA1B5AB373'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：explore 2025-09-27 16:16:46 - browse：3735

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Heart disease in astronauts blamed on cosmic radiation

hotspot

focus

explore

hotspot

focus

entertainment

Sen.ElizabethWarren(D-Mass.)KentNishimura/GettyImagesSenateDemocratsonThursdaysaidMedicareshouldtake

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Group behind ProMed defends move to subscription

PhRMA lawsuit over Medicare drug price negotiation tossed

The cancer stories no one wants to hear

Robert F. Kennedy is pitching centrism on health, even on abortion

For Medicare Advantage, Democrats want stronger protections around AI

explore

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

To avoid data mishandling cases, universities eye AI and other tools

Activists slam private health insurers over coverage restrictions

Pharma showers House GOP doctor with campaign cash

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A controversial new treatment promises to make little people taller

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves Sage Therapeutics’ rapid

Apple is now the first public company to be valued at $3 trillion

Doctors' information doesn't help them choose wisely when sick

focus

Medicare Advantage proposed rates disappoint insurers

The Readout: Gilead, Bernie Sanders, and other pharma news

Pharma showers House GOP doctor with campaign cash

Biogen Alzheimer’s drug launch off to slow start

How to ethically and practically extend health care to all

Medicare threatens to cut off funding for HCA's Mission hospital

explore

hotspot

focus

entertainment